Back to top

Xencor’s Promising Developments in Autoimmune and Oncology Drive Buy Rating

William Blair analyst Matt Phipps has reiterated their bullish stance on XNCR stock, giving a Buy rating today. Matt Phipps has given his Buy ratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Xencor, Inc. (XNCR)